About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00712504

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with...

Lead sponsor: Pfizer•5 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Advanced solid tumor malignancy ECOG 0 or 1

Exclusion Criteria

•Prior treatment with with high-dose chemotherapy requiring stem cell rescue Prior irradiation to ≥25% of the bone marrow (e.g. whole pelvis=25%) Patients with centrally located lung lesions unless recently treated with radiotherapy

Related studies

RECRUITINGPhase 1

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

NCT07042100 · Advanced Solid Tumors

RECRUITINGPhase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · Non Small Cell Lung Cancer

RECRUITINGPhase 1/2

Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

NCT07589530 · Advanced Solid Tumors, Metastatic Solid Tumors, and more

RECRUITINGPhase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

RECRUITINGPhase 1/2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 11, 2008Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment49

Start dateJul 2004

Last updatedNov 11, 2008

Condition

Advanced Solid Tumors Non Small Cell Lung Cancer

Locations shown

Pfizer Investigational Site

Birmingham, Alabama

Pfizer Investigational Site

Birmingham, Alabama

Pfizer Investigational Site

Birmingham, Alabama

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 11, 2008Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions